Nuplazid 34 MG capsule 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FDEM9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,589
Award facts
- Contract value 100% obligated
- $10,588.89 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count packaging). This firm fixed-price delivery order, issued on December 17, 2025, with an ultimate completion date of January 9, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that authorizes the issuance of delivery orders for pharmaceutical products supporting Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain since its registration in the System for Award Management in 2001. The company's primary IDC under the PPV-G GEN V program, designated SPE2DR with a $499.999 billion ceiling value and completion date of December 31, 2036, encompasses a 30-month base period with three 30-month option periods. The contractor operates without identified subcontractors and has demonstrated substantial performance across numerous delivery orders for diverse pharmaceutical products, including branded and generic medications, biologics, vaccines, and specialty pharmaceuticals, positioning it as a key regional pharmaceutical provider for Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FDEM9?
SPE2DR26FDEM9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FDEM9 worth?
The government has obligated $10,589 on SPE2DR26FDEM9.
Is contract SPE2DR26FDEM9 an order under another contract?
Yes. SPE2DR26FDEM9 is a delivery order under SPE2DR25D9112, an indefinite delivery contract.
Was contract SPE2DR26FDEM9 competed?
The extent of competition for SPE2DR26FDEM9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award